Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

Phase 1

Completed

• Conditions: Fabry Disease
• Interventions: Biological: Lentivirus Alpha-gal A transduced stem cells

• Registration Number: NCT02800070
• Lead Sponsor: University Health Network, Toronto

Brief Summary

This is a first-in-human study for the treatment of Fabry disease. Eligible patients will have an autologous stem cell transplantation using CD34+ cells that are transduced with the lentivirus vector containing the human alpha-gal A gene. The researchers of this study would like to see if the re-introduction of transduced cells will help increase the levels of alpha-gal A enzyme levels and to determine the safety and toxicity of autologous stem cell transplantation using CD34+ cells transduced with lentivirus vector containing the alpha-gal A gene. This study's objective is to determine the safety and toxicity of lentivirus alpha-gal A transduced CD34+ cells in adult males with Fabry disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-04-15
• Study First Submitted QC: 2016-06-09
• Study First Posted: 2016-06-15
• Study Start: 2016-07
• Status Verified: 2024-04
• Primary Completion: 2024-04
• Study Completion: 2024-04
• Last Update Submitted: 2024-04-16
• Last Update Posted: 2024-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 5

Inclusion Criteria

1. Male patients 18-50 years of age at the time of enrollment
2. Diagnosis of Fabry disease (FD) as defined by very low or absent α-gal A activity
3. Classic FD Type I phenotype with alpha-galactosidase A (GLA) genotyping
4. Patients on enzyme replacement therapy (ERT) prior to enrollment
5. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1
6. Adequate organ function within 21 days prior to Pre-Treatment Phase:
7. Willing and capable of signing and giving written informed consent in accordance with Research Ethics Board (REB) requirements
8. Willing to comply with all procedures outlined in the study protocol, cooperative with the protocol schedule, able to return for safety evaluation, or otherwise likely to complete the study
9. Willing to abstain from sexual activity or willing to use condoms during sexual intercourse from day of Melphalan administration on day -1 of Phase 3 until after 12 months follow-up post-transplant.
10. Willing to not donate sperm after receiving Melphalan. Sperm banking will be recommended to any patient who would like to father children in the future.

Exclusion Criteria

1. Males with variant Fabry Disease.
2. Female gender
3. Use of immunosuppressive agents or any anticoagulant
4. Ongoing ERT-related infusion associated reactions of moderate-to-severe intensity
5. Presence of anti-agalsidase immunoglobulin (Ig)G antibodies above a threshold (5-fold above normal;) or evidence of high titre neutralizing antibodies
6. Blood test positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), human T-cell lymphotropic virus type 1 (HTLV-2), or Venereal Disease Research Laboratory test (VDRL; Transmissible Disease (TD) testing will be done in Pre-Treatment Phase 2 - see section 5.1 for full panel of TD tests. Patients will only be excluded from the study if positive for the TD tests listed here in this exclusion).
7. Uncontrolled bacterial, viral, or fungal infections
8. Prior malignancies except resected basal cell carcinoma
9. Chronic Kidney Disease (CKD) stage >2
10. History of heart failure or left ventricle ejection fraction (LVEF) <45% or moderate to severe diastolic dysfunction by standard criteria
11. Arrhythmia: bundle branch block, heart block degree II or III, atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, cardiac arrest, pacemaker, implantable cardiac defibrillator
12. Coronary artery disease with angina, prior myocardial infarction, percutaneous transluminal coronary angioplasty with or without stent, coronary artery bypass graft surgery, moderate to severe valvular heart disease, valve replacement surgery
13. Uncontrolled hypertension
14. Diabetes mellitus
15. Advanced liver disease, liver failure, cirrhosis
16. Immune deficiency state
17. Moderate-to-severe chronic obstructive pulmonary disease (COPD)
18. Any hematological condition with white blood cells (WBC) <3.0 x109/L, platelet count <100 x109/L, and/or hemoglobin <100 g/L
19. Prior bone marrow transplant (BMT) or organ transplant
20. Any condition that would preclude use of Melphalan
21. Use of a drug with cytotoxic or immunosuppressive effect within 60 days of trial entry
22. Uncontrolled psychiatric disorder
23. Active chronic infection
24. Prior tuberculosis
25. Any other serious concurrent disease
26. Cognitive impairment that would prevent informed consent
27. Use of an investigational drug within 30 days of stem cell transplant (SCT)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment Arm	Lentivirus Alpha-gal A transduced stem cells	Patients will receive Health Canada approved transduced autologous CD34+ cell product.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	5 years	Safety measurement will be based on all clinical and laboratory assessment post-baseline. The assessment will be the frequency of clinically notable abnormal vital signs and laboratory values, and the frequency of treatment-related adverse events.

Secondary Outcome Measures

Name	Time	Method
vector copy number per genome on the CD34+ cell population	5 years	Persistence of LV-transduced cells as measured by quantitative (q)PCR
lyso-Gb3 levels	5 years	Reduction of lyso-Gb3 in plasma and urine
transduction efficiency	5 years	Number of colonies positive by PCR for the provirus out of number plated in the colony assay
lyso-Gb3 analogue (-28)	5 years	Reduction of lyso-Gb3 (-28) in plasma and urine
lyso-Gb3 analogue (-2)	5 years	Reduction of lyso-Gb3 (-2) in plasma and urine
Alpha-gal A enzyme activity levels	5 years	Increase in α-gal A enzyme activity within the plasma, leukocytes, and Bone marrow aspirate.
Gb3 levels	5 years	Reduction of Gb3 in plasma and urine
lyso-Gb3 analogue (+16)	5 years	Reduction of lyso-Gb3 (+16) in plasma and urine
lyso-Gb3 analogue (+34)	5 years	Reduction of lyso-Gb3 (+34) in plasma and urine
lyso-Gb3 analogue (+50)	5 years	Reduction of lyso-Gb3 (+50) in plasma and urine

Trial Locations

Locations (3)

Alberta Children's Hospital, University of Calgary; 🇨🇦 Calgary, Alberta, Canada

QE II Health Sciences Centre; 🇨🇦 Halifax, Nova Scotia, Canada

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada